Skip to main content
Fig. 3 | Cancer & Metabolism

Fig. 3

From: Characterizing OXPHOS inhibitor-mediated alleviation of hypoxia using high-throughput live cell-imaging

Fig. 3

OXPHOS inhibitors alleviate diffusion-limited hypoxia in a dose-dependent manner in spheroids. A The effect of Mito-PEG-ATO on hypoxia in B16OVA.HRE and MC38.HRE spheroids was monitored in the IncuCyte Live-cell imaging system. Spheroids were treated with 30 µM Mito-PEG-ATO or with 0.2% DMSO (control) 24 h after spheroid formation. B Quantification of the total hypoxia integrated intensity (the mean fluorescent intensity of the total hypoxic area multiplied by the size of the total hypoxic area) in B16OVA.HRE (red graphs) and MC38.HRE (blue graphs) spheroids compared to controls. T = 0 indicates the start of the formation of B16OVA.HRE and MC38.HRE spheroids. At t = 24, spheroids were treated with atovaquone, mito-atovaquone, PEGylated mito-atovaquone (Mito-PEG-ATO) or 0.2% DMSO (control). Data are presented as mean with SD, n ≥ 5

Back to article page

Cancer & Metabolism

ISSN: 2049-3002